-+ 0.00%
-+ 0.00%
-+ 0.00%

Cytek Biosciences Q3 net loss widens 11% year over year to $6.1 million

PUBT·11/04/2026 21:17:57
Listen to the news
Cytek Biosciences Q3 net loss widens 11% year over year to $6.1 million
  • Cytek Biosciences’ third-quarter 2026 net loss widened 11% year over year to $6.1 million.
  • Revenue rose year over year to $53.2 million, driven by U.S. growth and strong demand for high-end instruments.
  • GAAP gross margin climbed to 59%, while the installed instrument base reached 4,073.
  • Full-year 2026 revenue guidance narrowed to $208 million–$211 million, maintaining the midpoint.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytek Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611041605PRIMZONEFULLFEED9869858) on November 04, 2026, and is solely responsible for the information contained therein.